Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed renal cell carcinoma (RCC) * Clear cell or papillary RCC * Granular tumors with sarcomatoid features * No purely sarcomatoid RCC, chromophobic RCC, or oncocytoma * No transitional cell carcinoma of the renal pelvis and collecting systems * Metastatic or unresectable disease * At least 1 measurable lesion * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan * The following are not considered measurable: * Bone lesions * Leptomeningeal disease * Ascites * Pleural/pericardial effusion * Lymphangitis cutis/pulmonis * Abdominal masses that are not confirmed and followed by imaging techniques * Cystic lesions * Primary bladder masses * Progressive disease after interferon alfa and/or interleukin-2 for metastatic RCC OR intolerance to these therapies * No prior or concurrent CNS metastases * Negative MRI of the brain within the past 28 days * Must have HLA-identical (6/6) sibling donor PATIENT CHARACTERISTICS: Age: * 60 and under Performance status: * ECOG 0-1 Life expectancy: * More than 6 months Hematopoietic: * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 2 times upper limit of normal (ULN) * AST no greater than 3 times ULN Renal: * Creatinine clearance at least 40 mL/min Cardiovascular: * LVEF at least 45% by MUGA or echocardiogram Pulmonary: * DLCO greater than 40% of predicted (corrected for hemoglobin level) * No symptomatic pulmonary disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No known hypersensitivity to E. coli-derived products * No uncontrolled diabetes mellitus * No active serious infection * No other concurrent malignancy except non-melanoma skin cancer or other malignancy that has less than a 30% risk of relapse after completion of therapy PRIOR CONCURRENT THERAPY: Biologic therapy: * See Disease Characteristics * No concurrent sargramostim (GM-CSF) * Concurrent epoetin alfa allowed Chemotherapy: * No other concurrent chemotherapy Endocrine therapy: * At least 28 days since prior hormonal therapy (e.g., megestrol, corticosteroids, or anti-estrogen therapy) * Concurrent steroids allowed for adrenal failure, graft-versus-host disease, or other nondisease-related conditions (e.g., insulin for diabetes) Radiotherapy: * At least 14 days since prior radiotherapy Surgery: * At least 14 days since prior surgery Other: * At least 28 days since prior systemic therapy for RCC * Recovered from prior therapy